During the recent AWS Summit in Washington DC 2024, AWS unveiled its commitment to aiding startup companies in the advancement of generative AI. The company introduced the AWS Worldwide Public Sector Generative AI Impact initiative, promising to allocate $50 million over two years to support public sector organizations in expediting innovation in generative AI from June 26, 2024, to June 30, 2026.
This initiative encompasses the provision of up to USD 50 million in AWS Promotional Credits, in addition to training and technical expertise for generative AI projects. The distribution of credits will be contingent on various factors, including the customer’s proficiency in developing new technological solutions, project maturity, proof of prospective solution adoption, and the customer’s current expertise in generative AI.
The initiative is accessible to new or existing AWS global public sector customers and partners worldwide who are engaged in generative AI solutions aimed at addressing urgent societal issues.
Moreover, AWS has designated $10 million to endorse research in children’s healthcare and rare diseases. This encompasses the AWS IMAGINE Grant: Children’s Health Innovation Award, a $7 million strategic grant designed to promote proposals and provide funding for the utilization of cloud-native technologies, such as AI, to expedite pediatric research and enhance children’s health.
The initiative seeks to cultivate collaboration among hospitals and organizations employing cloud computing and AI to propel research and exploration. By streamlining data management in the cloud, researchers can obtain a more profound comprehension of the genetic composition of diseases, ultimately resulting in swifter, more precise diagnoses and tailored treatment plans for patients.
Adam Resnick, Director of the Center for Biomedical Data Mining at Children’s Hospital of Philadelphia (USA), conveyed his enthusiasm for the initiative, underscoring its compliance with the landscape of pediatric cancer as a rare disease. He stressed that it furnishes a distinctive platform for the application of advanced technologies, considering the persistent necessity for discoveries and close cooperation in disease treatment.